

POSTER PRESENTATION

Open Access

De-escalation of empiric antibiotic therapy in sepsis - an indian observational study

S Jakkinaboina*, K Swarna Deepak

From ESICM LIVES 2015

Berlin, Germany. 3-7 October 2015

Introduction

The guidelines for an appropriate use of antibiotic therapy recommend de-escalation as soon as the culture sensitivity results are available. There was a great need to study the frequency of de-escalation, no change and escalation of antibiotics and its impact in septic patients in an Indian ICU setting in view of rising burden of drug resistance and health care cost.

Objectives

To determine the rate of de-escalation of the empiric antimicrobial treatment in ICU patients admitted with sepsis. The characteristics of antimicrobial treatment associated with de-escalation & its impact on ICU length of stay, hospital length of stay (LOS) and 30 day mortality were determined.

Methods

We carried out a prospective observational study enrolling patients admitted to the ICU with sepsis from 01/02/2014 to 01/03/2015. Both the medical and surgical units of the

ICU were included. “**No change**” was defined as when empiric therapy was maintained without modification, “**Escalation of therapy**” was defined when there’s a switch to or addition of an antibiotic with a broader spectrum, and “**De-escalation**” when there’s a switch to or interruption of a drug class resulting in a less broad spectrum of coverage. If antimicrobial change consisted of escalation and de-escalation (i.e. switch to or addition of an antibiotic with a broader spectrum but also withdrawal of another antibiotic), the patient was assigned to “escalation group” for statistical analysis.

Results

The total number of patients enrolled were 315 out of which 17 patients were excluded due to death before culture results were available. The characteristics observed among the therapeutic strategy groups were seen in tables 1, 2.

The most common antibiotic after de-escalation & antibiotic in No Change group was Betalactam + beta lactamase inhibitor.

Table 1. Patient characteristics with therapeutic strategy

Variable	No change n	De-escalation n	Escalation n	P value
Number of patients	148	74	76	
Age in years	57.62	57.81	58.18	0.96
HOSPITAL length of stay in days	11.41	10.68	19.21	0.0001
APACHE II score at admission	15.3	15.84	20.11	0.0001
SOFA score at admission	6.07	6.65	8.08	0.004
Number of patients expired at 30 days after admission	20	10	26	0.0001
number of medical patients	144	64	66	0.003
Number of patients requiring vasopressors	20	16	34	0.0001
ICU length of stay in days	5.85	6.24	12.42	0.0001

Apollo Health City, Critical Care Medicine, Hyderabad, India

Table 2. Patient characteristics with therapeutic strategy

Variable	No change n	De-escalation n	Escalation n	P value
Number of initial empirical antibiotics 1	58	26	32	0.007
Number of initial empirical antibiotics 2	72	26	36	
Number of initial empirical antibiotics 3	18	22	8	
Most Common initial empirical antibiotic	beta lactam +beta lactamase inhibitor	Carbapenem	beta lactam +beta lactamase inhibitor	0.0001
Most Common Escalated /De-escalated Antibiotic	beta lactam +beta lactamase inhibitor	beta lactam +beta lactamase inhibitor	Carbapenem followed by colistin	0.0001
Multi drug resistant organisms	6	8	34	0.0001
ESBL organisms	4	4	10	0.0001
Most Common Source of infection	Lung	Lung	Lung	
H1N1 POSITIVE patients	29	10	6	0.062

Variable	Mean n	Standard deviation (%)
Age in years	57.81	15.34
ICU length of stay in days	7.62	7.98
HOSPITAL length of stay in days	13.21	11.43
APACHE II Score at admission	16.66	7.83
SOFA Score at admission	6.72	4.35
Number of Male patients	172	(57.72)
Mortality at 30 days	56	(18.79)
Number of medical patients	274	(91.95)
Number of Surgical Patients	24	(8.05)
Number of patients with Neutropenia	12	4.03
Number of Patients who required Vasopressors	70	(23.49)
Source as LUNG	186	(62.42)
Source as UROGENITAL TRACT	42	(14.09)
Number of patients with MDR organisms	48	(16.1)
Number of H1N1 Positive patients	45	(15.1)
Patients started with initial number of empirical antibiotics – 1	116	
1	116	(38.93)
2	134	(44.97)
3	48	(16.11)
Initial Empirical Antibiotic Betalactam + Betalactamase Inhibitor	134	(44.97)
Carbapenems	78	(26.17)
THERAPEUTIC STRATEGY APPLIED		
No Change	148	(49.66)
De Escalation	74	(24.83)
Escalation	76	(25.5)

Figure 1 The characteristics of the overall group of patients.

The statistically significant factors which increased the 30 day mortality are Escalation of antibiotics, Increased ICU LOS, Increased APACHE II and SOFA scores at admission, medical patients, vasopressor requirement,

lung as the source of infection, Infection with MDR organisms.

The statistically significant factors which increased the ICU LOS are use of vasopressors, Comorbidities,

VARIABLE	NON SURVIVORS AT 30 DAYS n	SURVIVORS AT 30 DAYS n	P VALUE
AGE in Years	59.86	57.34	0.29
ICU length of stay in days	9.75	7.13	0.027
Hospital length of stay in days	15.29	12.74	0.13
SOFA score at admission	9.64	6.05	0.0001
Number of Male patients	40	132	0.021
Number of Medical patients	52	222	0.781
Number of patients with Neutropenia	2	10	0.847
Number of patients who required Vasopressors	26	44	0.0001
Number of patients with Lung as source	40	146	
Number of patients with MDR organisms	20	30	0.0001
Number of patients with ESBL organisms	0	10	0.0001
Number of H1N1 infection	8	37	0.85
Patients with initial number of antibiotics			0.425
1	22	94	
2	22	112	
3	12	36	
Therapeutic Strategy Applied			0.0001
No Change	20	128	
De escalation	10	64	
Escalation	26	50	

Figure 2 Comparison between survivors and non survivors at 30 days.

Table 3 Prevalence of organisms in patient groups. The frequency of organisms in culture positive cases.

ORGANISM ISOLATED	NO CHANGE n	DE ESCALATION n	ESCALATION n	Total n (%)
Fungal infections	4	2	8	14(9.39%)
Non ESBL Gram Negative organisms	12	10	8	30(20.13%)
ESBL Gram negative organisms	4	4	10	18(12.08%)
MDR organisms	6	8	34	48(32.21%)
MRSA organisms	0	6	0	6(4.02%)
MSSA organisms	0	2	2	4(2.68%)
Vancomycin Resistant Enterococcus	2	0	0	2(1.34%)
Stenotrophomonas maltophilia	4	4	4	12(8.05%)

APACHE II at admission, SOFA at admission, MDR organisms, escalation of antibiotic.

Conclusions

Escalation of antibiotics resulted in statistically significant increase in the mortality and increased length of stay in the ICU and hospital. No significant differences were observed with respect to ICU length of stay, Hospital length of stay and 30 day mortality among No Change & De Escalation groups.

Published: 1 October 2015

Reference

1. Garnacho-Montero J, Gutiérrez-Pizarra A, Escobedo-Ortega A, Corcia-Palomo Y, Fernández-Delgado E, Herrera-Melero I, *et al*: De-escalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock. *Intensive Care Med* 2014, **40**:32-40.

doi:10.1186/2197-425X-3-S1-A405

Cite this article as: Jakkinaboina and Swarna Deepak: De-escalation of empiric antibiotic therapy in sepsis - an indian observational study. *Intensive Care Medicine Experimental* 2015 **3**(Suppl 1):A405.

Submit your manuscript to a SpringerOpen[®] journal and benefit from:

- Convenient online submission
- Rigorous peer review
- Immediate publication on acceptance
- Open access: articles freely available online
- High visibility within the field
- Retaining the copyright to your article

Submit your next manuscript at ► springeropen.com
